- A rise in high-sensitivity C-reactive protein (hsCRP) after acute coronary syndrome (ACS) was associated with elevated risk for major adverse cardiac event (MACE) and death within 4 months.
Why this matters
- After ACS, risks for further ischemic cardiovascular events and death are elevated.
- hsCRP measurements shortly after ACS have been linked to short-term outcomes, but it has been unclear whether serial measurements carry extra prognostic value.
- Adjusted HRs (95% CIs) with baseline and longitudinal hsCRP for:
- MACE: 1.36 (1.13-1.63; P=.001) and 1.15 (1.09-1.21; P<.001 class="">
- Cardiovascular death: 1.61 per SD (1.07-2.41; P=.02) and 1.26 per SD (1.19-1.34; P<.001>
- All-cause death: 1.58 per SD (1.07-2.35; P=.02) and 1.25 per SD (1.18-1.32; P<.001>
- Secondary analysis of double-blind, multicenter, randomized clinical VISTA-16 trial (n=4257).
- Patients presenting within 96 hours of ACS were randomly assigned to take investigative phospholipase A2 inhibitor vs placebo for 16 weeks.
- Researchers measured hsCRP at baseline and 1, 2, 4, 8, 16 weeks.
- Outcome: MACE (cardiovascular death, nonfatal myocardial infarction or stroke, or hospitalization for unstable angina).
- Funding: Anthera Pharmaceuticals.
- Drug being studied was linked to harm; hsCRP rise may have reflected that.